Novo Nordisk A/S (NYSE:NVO) Shares Down 2% – Time to Sell?

Novo Nordisk A/S (NYSE:NVO) was down 2% during trading on Thursday . The company traded as low as $37.85 and last traded at $38.0350. Approximately 17,014,226 shares were traded during trading, a decline of 35% from the average daily volume of 25,989,398 shares. The stock had previously closed at $38.83.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: WHO partnership expands global public‑health footprint and reputational reach — Novo committed nearly $8M to the WHO Foundation to support cardio‑renal‑metabolic disease initiatives in lower‑income markets; this supports long‑term brand and access objectives. Read More.
• Positive Sentiment: Zacks upgraded NVO from “strong sell” to “hold,” trimming one negative analyst signal and possibly limiting further forced selling from some quant/overlay strategies. Read More.
• Neutral Sentiment: Novo Holdings published 2025 annual results (income and investment returns reported), providing transparency on the largest shareholder’s position even as its NAV is stressed by NVO’s share move. This is a timing/structural note rather than new operational news for Novo Nordisk. Read More.
• Neutral Sentiment: Partnership with Hims & Hers could broaden telehealth access to Ozempic/Wegovy and shift demand from compounded GLP‑1s to branded therapies — potential long‑term demand tailwind but raises distribution and margin questions. Read More.
• Neutral Sentiment: Industry headwinds from regulatory guidance in large markets (e.g., India warning on weight‑loss advertising) may constrain marketing channels and local growth dynamics. Read More.
• Negative Sentiment: FDA warning letter cites failures in post‑marketing adverse‑event reporting related to semaglutide/GLP‑1 products; regulators have not said the drugs are unsafe, but the compliance issue sharply raises regulatory, inspection and remediation risk and is the primary catalyst for the share decline. Read More.
• Negative Sentiment: Regulatory scrutiny has triggered legal activity: Pomerantz LLP is investigating investor claims tied to recent disclosures — potential for securities litigation risk and related litigation expenses or settlements. Read More.
• Negative Sentiment: Analyst moves and downgrades (TD Cowen and others) and immediate sellside reactions have compounded pressure; the stock traded lower after these calls. Read More.
• Negative Sentiment: Coverage highlights that Novo Holdings’ assets have fallen sharply as NVO’s market value slumped — a visible reminder that continued share weakness can create broader investor/ownership volatility. Read More.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on NVO. Nordea Equity Research downgraded shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a research note on Tuesday, March 3rd. CICC Research started coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 price target on the stock. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Four investment analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $49.93.

Novo Nordisk A/S Stock Performance

The firm has a market cap of $169.83 billion, a price-to-earnings ratio of 10.96 and a beta of 0.73. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The stock has a fifty day moving average price of $50.69 and a 200-day moving average price of $52.02.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. On average, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The company also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s payout ratio is presently 52.74%.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Capital International Investors boosted its stake in Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after buying an additional 6,092,192 shares during the last quarter. Loomis Sayles & Co. L P increased its holdings in Novo Nordisk A/S by 6.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after purchasing an additional 969,916 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Novo Nordisk A/S by 5.1% during the 4th quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock valued at $748,064,000 after buying an additional 717,719 shares during the period. Morgan Stanley raised its holdings in shares of Novo Nordisk A/S by 3.5% during the 4th quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock valued at $653,406,000 after buying an additional 428,660 shares during the period. Finally, Folketrygdfondet grew its holdings in Novo Nordisk A/S by 1.2% during the 3rd quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock valued at $566,659,000 after purchasing an additional 117,370 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.